Omidubicel for Hematopoietic Cell Transplants: Considerations for Patients and Treatment Outcomes

For patients with hematologic malignancies requiring allogeneic stem cell transplantation, alternative donor sources are needed when lacking access to a matched related or unrelated donor. Umbilical cord blood (UCB) has been an important alternative allograft donor source for these patients; however...

Full description

Saved in:
Bibliographic Details
Published in:Patient preference and adherence 2024-01, Vol.18, p.2217-2223
Main Authors: Morse, Allison L, Kurz, Hana, Moore, Donald C
Format: Article
Language:English
Subjects:
Antithymocyte globulin
cellular therapy
Drug approval
hematology
hematopoietic cell transplant
Hematopoietic stem cells
Niacinamide
omidubicel
Review
Stem cells
Transplantation
Transplantation of organs, tissues, etc
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:For patients with hematologic malignancies requiring allogeneic stem cell transplantation, alternative donor sources are needed when lacking access to a matched related or unrelated donor. Umbilical cord blood (UCB) has been an important alternative allograft donor source for these patients; however, several limitations exist. Omidubicel is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy derived from UCB. Omidubicel was approved in May 2023 by the United States Food and Drug Administration based on the results of a Phase III trial comparing it to UCB transplantation in patients with high-risk hematologic malignancies. Median time to neutrophil engraftment was faster with omidubicel compared to UCB transplantation (12 days vs 22 days; p
ISSN:1177-889X
1177-889X
DOI:10.2147/PPA.S419253